VAZALORE, the first and only liquid-filled aspirin capsules approved by the United States Food and Drug Administration (FDA), is now available.
FREMONT, CA: PLx Pharma Inc., a specialty pharmaceutical company focused on developing more effective and safer products through its clinically validated and patent-protected PLxGuard™ drug delivery platform, including its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules, has now made VAZALORE available on shelves.
“We are excited that VAZALORE has hit the shelves nationally and look forward to communicating the benefits of this innovative aspirin therapy to millions of patients at risk for vascular disease,” states Natasha Giordano, Chief Executive Officer of PLx. “We are confident consumers will recognize VAZALORE as a breakthrough in aspirin delivery, designed to help protect the stomach while providing all of the benefits of aspirin to help prevent another heart attack or clot-related stroke.”
VAZALORE, the first and only liquid-filled aspirin capsules approved by the United States Food and Drug Administration (FDA), is available in the following strengths: VAZALORE 81 mg, 12 counts; VAZALORE 81 mg, 30 counts; and VAZALORE 325 mg, 30 counts.
VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides faster, more reliable, and predictable platelet inhibition than enteric-coated aspirin to patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation. Additionally, it decreases the incidence of stomach erosions and ulcers compared to immediate-release aspirin, which is frequently prescribed in an acute environment.
PLx Pharma Inc. is a specialized pharmaceutical firm dedicated to developing more effective and safer medications with its scientifically verified and patent-protected PLxGuard" drug delivery technology. The PLxGuard medication delivery platform delivers active medicinal components to specific gastrointestinal (GI) tract regions. PLx believes that this platform can significantly increase the absorption of a wide variety of pharmaceuticals now on the market or in development and lessen the risk of stomach erosions and ulcers associated with certain medications.